New Two-Step therapy shows promise against chronic hepatitis b

NCT ID NCT05276297

Completed Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 25 times

Summary

This study tested a new two-step treatment for adults with chronic hepatitis B who are already on standard antiviral medication. The treatment involves first giving an experimental drug (ASO) for 12 or 24 weeks, followed by a targeted immunotherapy. The goal was to see if this approach is safe and can help control the virus better than standard therapy alone. 174 participants took part in this phase 2 trial.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

GSK Investigational Site

Edegem, 2650, Belgium
GSK Investigational Site

Sliven, 8800, Bulgaria
GSK Investigational Site

Sofia, 1407, Bulgaria
GSK Investigational Site

Sofia, 1431, Bulgaria
GSK Investigational Site

Sofia, 1784, Bulgaria
GSK Investigational Site

Sofia, 1797, Bulgaria
GSK Investigational Site

Veliko Tarnovo, 5000, Bulgaria
GSK Investigational Site

Vratsa, 3000, Bulgaria
GSK Investigational Site

Clichy, 92118, France
GSK Investigational Site

Créteil, 94010, France
GSK Investigational Site

Lyon, 69317, France
GSK Investigational Site

Strasbourg, 67091, France
GSK Investigational Site

Berlin, 10787, Germany
GSK Investigational Site

Frankfurt, 60590, Germany
GSK Investigational Site

Leipzig, 04103, Germany
GSK Investigational Site

Pokfulam, Hong Kong
GSK Investigational Site

Bergamo, Italy
GSK Investigational Site

Milan, 20122, Italy
GSK Investigational Site

Milan, 20157, Italy
GSK Investigational Site

Roma, 00133, Italy
GSK Investigational Site

Rozzano MI, 20089, Italy
GSK Investigational Site

Makati City, 1229, Philippines
GSK Investigational Site

Pasig, 1605, Philippines
GSK Investigational Site

Krakow, 31-202, Poland
GSK Investigational Site

Mysłowice, 41-400, Poland
GSK Investigational Site

Łańcut, 37-100, Poland
GSK Investigational Site

Cluj-Napoca, 400162, Romania
GSK Investigational Site

Craiova Dolj, 200515, Romania
GSK Investigational Site

Singapore, 119074, Singapore
GSK Investigational Site

Singapore, 169608, Singapore
GSK Investigational Site

Barcelona, 08011, Spain
GSK Investigational Site

Madrid, 28006, Spain
GSK Investigational Site

Madrid, 28007, Spain
GSK Investigational Site

Madrid, 28034, Spain
GSK Investigational Site

Madrid, 28046, Spain
GSK Investigational Site

Madrid, 28222, Spain
GSK Investigational Site

Santander, 39008, Spain
GSK Investigational Site

Seville, 41013, Spain
GSK Investigational Site

Vigo, 36071, Spain
GSK Investigational Site

Chiayi City, 600, Taiwan
GSK Investigational Site

Kaohsiung City, 807, Taiwan
GSK Investigational Site

Linkou - Taoyuan Hsien, 333, Taiwan
GSK Investigational Site

Taichung, 404, Taiwan
GSK Investigational Site

Taichung, 40705, Taiwan
GSK Investigational Site

Tainan, 704, Taiwan
GSK Investigational Site

Bangkok, 10330, Thailand
GSK Investigational Site

Chiang Mai, 50200, Thailand
GSK Investigational Site

Istanbul, 6690, Turkey (Türkiye)
GSK Investigational Site

Rize, 53200, Turkey (Türkiye)
GSK Investigational Site

Cottingham, HU16 5JQ, United Kingdom
GSK Investigational Site

Leicester, LE1 5WW, United Kingdom

Conditions

Explore the condition pages connected to this study.

HEPATITIS B, CHRONIC